Previous Article | Next Article 
Journal of Virology, July 2001, p. 6033-6041, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.6033-6041.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus SM Protein Interacts with mRNA
In Vivo and Mediates a Gene-Specific Increase in Cytoplasmic
mRNA
Vivian
Ruvolo,1
Ashish K.
Gupta,1 and
Sankar
Swaminathan1,2,*
University of Florida Shands Cancer
Center1 and Department of Medicine and
Department of Molecular Genetics & Microbiology,2 University of Florida,
Gainesville, Florida 32610
Received 16 January 2001/Accepted 3 April 2001
 |
ABSTRACT |
SM is an Epstein-Barr virus (EBV) gene expressed during early lytic
replication of EBV. SM encodes a nuclear phosphoprotein that functions
as a posttranscriptional regulator of gene expression. SM has been
implicated in several aspects of gene regulation, including nuclear
mRNA stabilization, posttranscriptional processing, and nuclear mRNA
export. Activation by SM is promoter independent but gene specific. The
mechanism by which SM selectively activates some EBV target genes or
heterologous reporter genes remains to be determined. SM binds RNA in
vitro, suggesting that sequence- or structure-specific mRNA
interactions might mediate SM specificity. We have further analyzed RNA
binding by SM and demonstrated that proteolytic cleavage of SM and
consequent exposure of an arginine-rich region are necessary to allow
RNA binding in vitro. However, SM mutants with deletions of this
arginine-rich region localized normally in the nucleus and were fully
functional in gene activation. We therefore developed an assay to study
in vivo interactions of SM with target mRNAs based on
immunoprecipitation of SM from cell lysates followed by RNase
protection analysis. Using this assay, we demonstrated that SM forms
complexes with specific mRNAs in vivo. SM binds mRNAs from both
SM-responsive as well as nonresponsive intronless genes and increases
the nuclear accumulation of both types of mRNAs. In addition, SM
preferentially associates with newly transcribed mRNAs. These data
indicate that SM forms complexes with mRNAs in the nucleus and enhances
their nuclear accumulation. However, SM does not enhance cytoplasmic
accumulation of all transcripts that it binds to the same degree,
suggesting that additional mRNA-specific characteristics, such as
nuclear retention motifs or binding sites for cellular proteins, also
determine responsiveness to SM.
 |
INTRODUCTION |
The Epstein-Barr virus (EBV) nuclear
phosphoprotein SM, also referred to as EB2 and Mta, is a
posttranscriptional regulator of gene expression (9, 30, 35,
45). The SM protein is expressed from an early gene during lytic
EBV replication (10, 46). Although SM has been extensively
studied, many aspects of its mechanism of action remain incompletely
understood. We and others have shown that SM activates expression of
the chloramphenicol acetyltransferase (CAT) gene, when cotransfected,
in a variety of cell types (6, 9, 30, 31, 35, 45, 53).
Steady-state levels of both cytoplasmic and nuclear CAT mRNAs
increase in SM-transfected cells (45). The increase in CAT
activity corresponds well with the increased amount of cytoplasmic CAT
mRNA seen with SM transfection (12, 45). SM does not
affect the rate of CAT mRNA transcription as measured by nuclear run-on
transcription assays (45). Activation of CAT by SM is also
independent of the promoter used to transcribe CAT mRNA. These data,
taken together, demonstrate that SM has a posttranscriptional mechanism
of action.
The herpes simplex virus (HSV) homolog of SM, ICP27, is a global
inhibitor of host cell splicing and is thought to generally inhibit
expression of intron-containing genes (21, 22). The majority of HSV lytic genes are intronless, and it has been suggested that ICP27 may play a role in facilitating selective expression of
intronless HSV genes (47). Investigators from our
laboratory have reported that introduction of heterologous introns into
otherwise identical CAT reporter plasmids results in inhibition rather
than activation by SM (45). We also reported that SM
inhibits expression of the human growth hormone (hGH) gene, which
contains four introns, and also of the spliced EBV BZLF1 gene.
SM-mediated inhibition was demonstrated to occur at the
posttranscriptional level. However, others have found that SM increases
cytoplasmic accumulation of some intron-containing transcripts
(4). The effect of SM on intron-containing genes is
therefore incompletely characterized, and the effect of SM on a
specific intron-containing gene may be dependent on multiple
gene-specific factors, such as the nature of the splicing signals and
other posttranscriptional processing signals.
A distinct property of SM-mediated activation is its gene specificity.
Specifically, SM activates some reporter genes, such as CAT, but not
others, such as
-galactosidase or hGH (30, 45). SM
transfection also induces increased cytoplasmic accumulation of several
lytic EBV transcripts. SM enhances cytoplasmic accumulation of mRNA
from the EBV replicative genes BMRF1, BALF2, BALF5, BSLF1, and BBLF4,
but not BBLF2/3 (50). The nonresponsiveness of BBLF2/3 to
activation by SM persisted even when a potential intron was removed
from the BBLF2/3 gene. Homologs of SM are present in several human
herpesviruses, including HSV, cytomegalovirus (CMV), and Kaposi's
sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus
8) (1, 7, 14, 20, 33, 40, 44, 52). We have shown that the
KSHV homolog of SM also demonstrates selective activation of target
genes in transfection assays (20). Activation by ICP27 is
also target gene dependent, and it has been suggested that its
specificity is based on the ability of ICP27 to selectively bind
different mRNAs (47). Recently, it has also been shown that ICP27 leads to increased nuclear and cytoplasmic accumulation of
intron-containing transcripts of the cellular alpha-globin gene
(8, 16). Thus, it appears that there may be gene-specific signals, independent of the presence of introns, that determine the
responsiveness of an individual gene to activation by SM and perhaps by
other herpesvirus homologs.
Recombinant SM binds several mRNAs in vitro, suggesting that SM
interacts with target mRNAs and enhances their stability or processing
(45, 50). SM shuttles from nucleus to cytoplasm in a
heterokaryon assay and translocates to the cytoplasm in response to
overexpression of CRM 1 (exportin 1) (2, 50). Other
investigators have also reported SM-mediated effects on nuclear RNA
export that are CRM-1 independent (17). These findings
indicate that SM could function by binding target mRNAs and enhancing
their nucleocytoplasmic export. Physical interaction of SM with
pre-mRNA and mRNA of target genes could also explain many of the
gene-specific aspects of SM function outlined above. In this context,
it is significant that SM has been reported to bind a fragment of RNA
transcribed from BMRF1, an SM-responsive EBV gene, but not an unrelated
cellular RNA, in vitro (50). We undertook the present
study to further characterize SM-mRNA interactions and to determine
whether the gene specificity of activation by SM is due to an ability
to differentially bind various mRNA targets.
 |
MATERIALS AND METHODS |
Cells and plasmids.
BJAB cells (43) were
cultured in RPMI 1640 tissue culture medium supplemented with 10%
fetal bovine serum. COS-7 cells (19) were cultured in
Dulbecco's modification of Eagle's medium supplemented with 10%
fetal bovine serum.
SM, aSM, and CMV-CAT have been previously described (45).
CMV-hGH was made by inserting a
HindIII-to-SmaI fragment containing the
entire hGH cDNA (15) into pcDNA 3.1 (Invitrogen, Carlsbad, Calif.). CMV-luc was constructed by inserting a
HindIII-to-XbaI fragment containing the
luciferase coding sequence from pGL3-Promoter (Promega, Madison, Wis.)
into pcDNA 3.1. CMV-cGAPDH was constructed by inserting the
PvuI-to-FspI fragment containing the human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA from pHcGAP
(51) into pcDNA 3.1. This fragment also contained 126 bp
of the
-lactamase gene from pBR322 located 5' to the GAPDH cDNA in pHcGAP.
Construction of glutathione
S-transferase (GST)-SM fusion
plasmids in a derivative of pGEX has been previously described
(
45).
Truncations of SM consisting of amino acids (aa) 1 to 149, 1 to
185, and 1 to 281 were constructed by subcloning the
fragments
of SM from
BglII-to-
SmaI,
-
XhoI, or -
HincII, respectively, in
frame with
GST. Deletion mutants (

RXP and

281) were constructed
by removing
the internal
SmaI-
XhoI fragment from the
full-length
GST-SM and the GST-1-281 fusion plasmid,
respectively.
Plasmid templates for in vitro RNA probe synthesis were constructed in
pBluescript (Stratagene, La Jolla, Calif.). The CAT
template pRP1
consisted of a 514-bp
SspI fragment derived from
pLGU
(
45), containing the complement to the 3'-terminal 135
residues of the CAT mRNA (
49). The luciferase template
pVR193
was constructed with a 350-bp DNA fragment from pGL3-Basic
(Promega),
encoding the 3'-terminal 350 residues of the luciferase
mRNA,
and a 125-bp fragment from bacteriophage lambda to allow
differentiation
of full-length probe from the protected fragment. The
GAPDH template
was constructed with a 1.0-kb
HindIII
fragment from pHcGAP containing
the 5'-terminal 172 bp of the human
GAPDH gene (
54). The template
for probe to specifically
detect mRNA transcribed from transfected
CMV-cGAPDH consisted of a
355-bp
PvuI-
HindIII fragment from pHcGAP
containing 126 bp of pHcGAP 5' to the initiator codon of GAPDH
and 229 bp of the amino-terminal portion of the GAPDH
gene.
Transfections and reporter gene assays.
BJAB cells were
transfected by electroporation with 10 µg of each plasmid, as
previously described (45). Lysates were prepared 48 h
after electroporation. CAT assays and radioimmunoassays for hGH were
performed as previously described (45). Luciferase assays
were performed with beetle luciferin as a substrate per the
manufacturer's protocol (Promega). COS-7 cells were transfected with
Lipofectamine Plus (Life Technologies, Gaithersburg, Md.) as previously
described (2).
RNA methods.
For RNA isolation, cells were harvested 48 h after transfection and lysed in 0.5% Nonidet P-40 (NP-40) buffer.
Nuclei were separated by centrifugation, and RNA was prepared from
cytoplasmic and nuclear fractions as described previously
(11). Selection of poly(A)+ RNA was performed
as described previously (45). Detection of in vitro RNA
binding by SM fusion proteins was performed by hybridization of
radiolabeled RNA probes to proteins transferred to membranes as
previously described (45).
Assay for in vivo RNA binding: IP-RPA.
Confluent monolayers
of transfected COS-7 cells were scraped from tissue culture flasks and
washed with phosphate-buffered saline. Cell pellets were lysed in
ice-cold immunoprecipitation (IP) lysis buffer (25 mM Tris, 150 mM NaCl
[pH 7.4], 1% Triton X-100, 1 mM dithiothreitol, 400 U of human
placental RNase inhibitor [Amersham Pharmacia, Piscataway, N.J.] per
ml, and protease inhibitor cocktail [P2714; Sigma, St. Louis, Mo.]).
Cells were incubated in lysis buffer for 15 min and centrifuged for 5 min at 4°C and 13,000 × g. Supernatants were
precleared with preimmune rabbit serum and protein A-agarose beads
(Life Technologies) for 1 h at 4°C. Lysates were then incubated
with gentle rocking at 4°C with polyclonal rabbit anti-SM serum or
with preimmune rabbit serum for 30 min. Protein A-agarose beads were
then added and the incubation was continued for an additional 90 min.
The immunoprecipitates were washed extensively with RNase-free lysis
buffer and then treated with 1,430 µg of proteinase K (Roche
Molecular Biochemicals, Indianapolis, Ind.) per ml for 1 h at
37°C in a solution containing 10 mM Tris-HCl (pH 7.0), 0.5 M NaCl, 1 mM EDTA, and 0.05% sodium dodecyl sulfate. The resulting material was
then extracted with phenol-chloroform (50% [vol/vol]) and ethanol
precipitated with the addition of 140 µg of yeast tRNA/ml as a
carrier. RNA immunoprecipitated in this manner was then analyzed by
RNase protection assay (RPA). 32P-labeled probes for RPA
were generated by in vitro transcription from the plasmid templates
described above. Plasmids were linearized with the appropriate
restriction enzyme, phenol extracted, and transcribed in vitro with
either T7 or T3 RNA polymerase (New England Biolabs, Beverly, Mass.,
and Promega, respectively) and [
-32P]UTP, as per the
manufacturer's protocol. Probes were purified by DNase treatment,
phenol extraction, and Sephadex G50 gel filtration. Sample RNA (either
from IP or directly isolated from transfected cells) was hybridized
overnight with 2.5 × 106 cpm of RNA probe at 42°C
in a solution containing 80% formamide, 400 mM NaCl, 40 mM
piperazine-N,N'-bis(2-ethanesulfonic acid) (pH
6.4). In each hybridization with immunoprecipitated RNA, the RNA sample
represented material from 1.25 × 105 transfected
cells. Control hybridizations with radiolabeled probe and tRNA instead
of sample RNAs were performed in parallel. Hybridization reaction
mixtures were diluted 20-fold, and unprotected probe was hydrolyzed by
treatment with 30 U of RNase T2 (Life Technologies) per ml
for 1 h at 37°C. The reactions were terminated with sodium dodecyl
sulfate and precipitated with 130 µg of carrier yeast tRNA/ml and
ethanol. Samples were electrophoresed on 6 or 8% polyacrylamide gels
containing 8 M urea, dried, and autoradiographed.
 |
RESULTS |
Arginine-rich region of SM is required for RNA binding in vitro but
is not required for transactivation function or nuclear
localization.
Two arginine-rich regions of ICP27, the HSV homolog
of SM, have been implicated in RNA binding in vitro and in vivo
(42, 47). Although it does not contain well-defined RNA
recognition motifs, the SM protein sequence encodes an arginine-rich
region from aa 152 to 182 (18). This region contains 11 arginines, including eight triplet repeats of the pattern RXP, where X
is usually alanine. Our investigators have previously shown that bacterially produced SM-GST fusion proteins can bind radiolabeled RNA
molecules in vitro (45). Similar findings were also
reported by Semmes et al. (50). We found that the
RNA-binding capacity was located in the amino-terminal half of the
protein. Specifically, a fusion protein consisting of GST and aa 1 to
281 of SM was shown to be capable of binding labeled CAT mRNA when
bound to membranes (Northwestern assay) as well as in solution
(45). In order to further delineate the region of SM
involved in binding RNA in vitro, we performed Northwestern assays with
several internally deleted or truncated mutants of SM fused to GST.
Three fusion proteins consisting of GST fused with full-length SM, aa 1 to 281, or aa 1 to 185 were synthesized in bacteria. Three
corresponding deletion mutants were also produced in which the
arginine-rich regions (aa 149 to 185) were removed (Fig.
1A). The results of a Northwestern assay
performed with these fusion proteins and a CAT RNA probe are shown in
Fig. 1B. All three fusion proteins which contained the arginine-rich
region (SM, 281, and 185) bound RNA, whereas all three RXP-deleted
fusions (
RXP,
281, and
185) did not. Thus, deletion of aa 149 to 185 completely abolished the ability of any of the SM fusion
proteins to bind the probe RNA, indicating that this region was
required for RNA binding. Surprisingly, although the length of the
different fusion proteins varied, the size of the protein which bound
RNA on Northwestern assay was the same in all cases, approximately 55 kDa (Fig. 1B). Examination of the wild-type SM-GST fusion protein on
Coomassie-stained gels revealed, in addition to a band at the expected
size (90 kDa), an additional prominent doublet band at approximately 55 kDa (Fig. 1C). A similar band of identical mobility at approximately 55 kDa was also seen with the 281 lysate. Taking into account the
contribution of GST to the size of the fusion protein, these data
indicate that a proteolytic site was present at approximately the
center of the arginine-rich region in SM. Consistent with such an
interpretation is the finding that when the arginine-rich region was
removed (as in
RXP and
281), only a band of the expected size for
the fusion protein was present and no smaller cleavage product was seen
(Fig. 1C).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of in vitro RNA binding by SM mutants. (A)
Structure of GST-SM fusion proteins. GST fused to the amino terminus of
SM mutants is shown in gray. Amino acids at sites of deletion or
truncation are shown above each diagram. The arginine-rich region (RXP
repeats) is shown with diagonal lines. Potential cleavage sites in the
arginine-rich region are depicted by the wavy line. (B) Northwestern
assay. Lysates of bacteria expressing full-length or mutant SM fusion
proteins were electrophoresed, transferred to polyvinylidene difluoride
membranes, and probed with single-stranded radioactively labeled CAT
RNA probe. Molecular masses are shown at right in kilodaltons. (C)
Coomassie-stained gel of proteins analyzed by Northwestern assay in
panel B. Locations of full-length GST-SM (upper arrow) and its major
cleavage product (lower arrow) are shown at left. Molecular masses are
shown at right in kilodaltons.
|
|
As is clear from the Northwestern assay (Fig.
1B) and although they
contain the RXP domain, the intact (uncleaved) forms of
SM and 281 do
not bind RNA in vitro. Therefore, it appears that
cleavage at the
proteolytic site, resulting in the exposure of
an arginine-rich region
at the carboxy terminus of the protein
fragment, is required for in
vitro RNA binding. It has been previously
reported that a deletion
mutant of SM, similar to

RXP, is capable
of mediating RNA export
(
4). Coupled with these data, our findings
suggested that
in vitro RNA binding by SM may not be relevant
to its in vivo function.
In order to determine whether

RXP SM,
which is completely unable to
bind RNA in vitro, nevertheless
retains some or all of its activation
function, we compared the
ability of

RXP SM and wild-type (wt) SM to
activate CAT in a
cotransfection assay. BJAB cells (from an
EBV-negative B-cell
lymphoma) were transfected with wt or

RXP SM
expression plasmid
and a CMV promoter-driven CAT reporter plasmid by
electroporation.
As shown in Fig.
2A,

RXP was fully functional in its ability
to activate CAT expression.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Transactivation function and cellular localization of
the RXP mutant. (A) Activation of CAT by RXP and SM. BJAB cells
were transfected with CMV-CAT reporter plasmid and either RXP, SM,
or control plasmid. CAT assays were performed on cellular lysates
36 h after transfection. (B) Measurement of CAT RNA in
RXP-transfected cells. BJAB cells were transfected with CMV-CAT
reporter plasmid and either RXP or control plasmid. RNA was isolated
from cytoplasmic (C) and nuclear (N) fractions and analyzed by Northern
blotting with CAT probe. (C) Nuclear localization of SM and RXP.
COS-7 cells were transfected with either SM or RXP. Forty-eight
hours after transfection, cells were washed, fixed, and stained with
polyclonal anti-SM antibodies and Texas Red-labeled secondary
antibodies.
|
|
We also wished to confirm that

RXP enhanced cytoplasmic and nuclear
accumulation of target mRNA in a manner similar to wt
SM. We therefore
isolated cytoplasmic and nuclear RNA from BJAB
cells transfected with
CMV-CAT plasmid and either

RXP or control
plasmid and performed
Northern blotting using a CAT probe. As
shown in Fig.
2B,

RXP
strongly enhanced accumulation of CAT mRNA
in both nucleus and
cytoplasm. These data therefore indicate that
SM-mediated activation
and enhanced RNA accumulation do not require
the arginine-rich
domain.
We next examined whether the intracellular localization of SM was
affected by deletion of the in vitro RNA-binding domain.
Arginine-rich
motifs are commonly found in regions involved in
both RNA binding and
nuclear localization. For example, arginine-rich
regions of ICP27 are
required for nuclear localization, and certain
HSV ICP27 mutations that
alter RNA binding also affect their nuclear
distribution (
23,
42). COS-7 cells were transfected with either

RXP or wt SM
plasmid and examined by immunofluorescence 48 h
after
transfection. As shown in Fig.
2C, deletion of the RXP motifs
does not
affect the nuclear staining pattern of SM. Thus, the
ability of SM to
bind RNA in vitro is completely dispensable for
transactivation of CAT
and for proper nuclear localization of
the SM protein. These findings,
although somewhat surprising,
do not exclude the possibility that SM
binds RNA in vivo, either
directly or indirectly, via other
proteins.
SM binds mRNA in vivo.
Although the ability of SM to bind RNA
in vitro did not correlate with its activation function, many aspects
of SM activity suggest that it interacts with the mRNA of its target
genes in vivo. We therefore wished to determine whether SM protein
could bind RNA in vivo and developed the following assay to measure mRNA binding by SM in transfected cells. First, target RNAs and SM or
SM mutant proteins were expressed in COS-7 cells by transfecting plasmids encoding the target CAT gene and CMV promoter-driven SM or
mutant-SM expression vectors. Forty-eight hours after transfection, the
cells were lysed in the presence of both protease and RNase inhibitors.
A fraction of the lysate was reserved for RNA and protein analysis, and
the remainder was immunoprecipitated with either anti-SM antibodies or
preimmune serum. Any RNA that was coimmunoprecipitated was isolated by
protease treatment followed by extraction with phenol and ethanol
precipitation. The presence of specific mRNAs in the immunoprecipitates
was then quantitated using an RPA. The results of a representative
experiment are shown in Fig. 3A. SM
immunoprecipitates contained clearly detectable CAT mRNA. Comparison
with the amount of CAT mRNA present in RNA isolated directly from the
same cell lysate as used for the IP (Fig. 3A, lane R) indicated that
approximately 10% of the total CAT mRNA in the cells was present in an
immunoprecipitable complex with SM.
RXP, which lacks the in vitro
RNA binding domain, also bound CAT mRNA in vivo, with an efficiency
indistinguishable from that of wt SM. RPA was performed simultaneously
with antisense RNA probes specific for CAT and GAPDH, an abundant
cellular transcript. Although GAPDH mRNA was easily detectable in the
total RNA (as seen in Fig. 3A, lane R), it was not present in the
anti-SM immunoprecipitates, demonstrating that the association of CAT
mRNA with SM was, to some degree, specific. Controls were performed
with preimmune serum and SM-transfected cells or with anti-SM
antibodies and control vector-transfected cells. These were both
negative for the presence of CAT mRNA (Fig. 3A). A carboxy-terminal
deletion mutant of SM (
C) which is nonfunctional and poorly soluble
(data not shown) also did not form immunoprecipitable complexes with CAT mRNA.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 3.
In vivo binding of RNA by SM and SM mutants. (A) COS-7
cells were transfected with CMV CAT and either control vector (C), SM,
RXP, or C mutants. Lysates from transfected cells were
precipitated with either preimmune serum ( ) or anti-SM antibodies
(+). RNA was prepared from immunoprecipitates and analyzed by RPA to
detect CAT and GADPH RNAs. Locations of protected GADPH and CAT
fragments are shown at left. RPA was also performed using total RNA
from CAT- and SM-transfected cells (R) or tRNA (t) as a control.
Full-length probe is shown in lane labeled f.l. mw, molecular size
markers. (B) Immunoprecipitates from cells transfected with either
vector plasmid (C), SM, or RXP were electrophoresed and
immunoblotted with anti-SM antibodies. Lysates were immunoprecipitated
with anti-SM antibodies or with preimmune serum.
|
|
Although

RXP is not cleaved when produced in bacteria and is fully
competent to bind CAT mRNA in vivo, as shown above, it
was nevertheless
possible that a cleaved fragment of wt SM was
produced in vivo and was
responsible for some of the binding capacity
observed in the IP-RPA
experiments. We therefore reserved a fraction
of the immunoprecipitates
used for the RPA and analyzed them by
immunoblotting with
anti-SM antibodies. As shown in Fig.
3B, full-length
SM
was present in the immunoprecipitates from SM-transfected cells
and a cleavage product was not detected. Therefore, exposure of
the
arginine-rich region by proteolytic cleavage or truncation
during
synthesis, as observed in bacteria and required for in
vitro RNA
binding, does not occur in mammalian cells and is not
required for in
vivo RNA
binding.
Gene-specific activation by SM correlates with ability of SM to
enhance cytoplasmic accumulation of target gene mRNAs.
SM
activates genes by a promoter-independent mechanism. Expression of
reporter genes is activated by SM when they are transcribed from either
EBV or other heterologous viral promoters (30). Activation
of a variety of bacterial and cellular reporter genes as well as EBV
genes has been demonstrated to occur at the posttranscriptional level
(5, 30, 45). Nevertheless, activation by SM is gene specific. For example, in cotransfection assays, SM increases the
cytoplasmic accumulation of mRNAs for several EBV genes involved in
DNA replication but not of that for the BBLF2/3 gene (50). Similarly, in earlier studies it had been reported that expression of
CAT, but not
-galactosidase, was activated by SM (30).
The basis for these differences has remained unclear. In order to further study the mechanism of selective activation by SM, we compared
the effect of SM on three commonly used reporter genes whose expression
is easily quantitated at the RNA and protein levels. BJAB cells were
cotransfected with either SM or antisense control plasmid and the
reporter plasmid. In these experiments, the reporter plasmids encoded
hGH cDNA, luciferase, or CAT. SM strongly increased the expression of
CAT, as has been demonstrated previously, and the increase in protein
activity corresponded well with the increase in cytoplasmic CAT mRNA
(approximately 10-fold) (Fig. 4).
However, SM did not increase the level of luciferase activity or the
amount of secreted hGH (Fig. 4A). As shown in Fig. 4B, the accumulation
of luciferase or GH mRNA in the cytoplasm was also not increased by SM.
One possible explanation for these findings is that SM is able to bind
some RNAs but not others. Such specific binding could potentially
result in the stabilization and/or increased nuclear export of
some but not all mRNAs. It should be noted that there is a
moderate increase in the nuclear accumulation of all three mRNAs when
SM is cotransfected (approximately two- to threefold), which we have
observed consistently (data not shown).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 4.
Gene-specific activation by SM. (A) Effect of SM on
protein expression. BJAB cells were transfected with either control
vector ( SM) or SM expression vector (+SM). CAT lysates were prepared
48 h later, and protein levels were measured. CAT assays were performed
with [14C]chloramphenicol. Thin-layer chromatography was
performed and quantitated by direct counting of acetylated fractions.
Luciferase activity was measured with a luminometer, and hGH was
measured by radioimmunoassay. Each value represents the mean of three
individual experiments, and error bars represent the standard error of
the mean. (B) Effect of SM on nuclear and cytoplasmic RNA levels. BJAB
cells were transfected as for panel A and RNA was prepared from nuclear
and cytoplasmic fractions. Ten micrograms of each RNA was
electrophoresed, transferred to nylon membrane, and hybridized to
radiolabeled hGH, luciferase, or CAT DNA probe. Each blot was stripped
and rehybridized to GAPDH probe to verify equal loading.
|
|
Differential mRNA binding is not the basis for gene specificity of
SM-mediated activation.
Because SM had clearly distinguishable
effects on the accumulation of different mRNAs, we wished to determine
whether the efficiency of mRNA binding by SM in vivo depended on the
sequence of the specific target mRNA. Such an ability to discriminate
between various mRNA targets could allow SM to specifically activate
some but not all EBV genes. Intronless genes are known to be inherently poorly expressed, and the expression of many viral genes lacking introns is known to be facilitated by the presence of specific RNA
sequences that permit the binding of cellular or viral proteins that
increase their cytoplasmic accumulation. Examples include human
immunodeficiency virus (HIV) RNAs with rev-responsive elements, the HSV
thymidine kinase gene, which contains an hnRNP L-binding motif, and the
constitutive transport element of type D retroviruses (3, 36,
38). Importantly, ICP27, the HSV homolog of SM, has been
reported to bind some lytic HSV mRNAs with greater affinity than others
(47). We therefore applied our assay to ask whether SM
bound the mRNAs of a responsive target gene (CAT) with greater avidity
than it bound the mRNA of a nonresponsive target (luciferase). As in
the previous experiments, COS-7 cells were transfected with SM plasmid
and either CMV-luciferase or CMV-CAT. Equal numbers of cells from
SM-luciferase and SM-CAT transfections were pooled and lysed together.
Aliquots were reserved for direct preparation of RNA, and the remainder
of the lysates was immunoprecipitated with either anti-SM antibodies or
preimmune serum. RNA was isolated from the immunoprecipitates and
subjected to an RPA using probes for the luciferase and CAT genes
simultaneously. RNA prepared directly from the transfected cells was
analyzed in parallel as a measure of the relative amounts of luciferase
and CAT mRNAs present in the cells (Fig.
5). As in the previous experiments, CAT
mRNA was precipitated by anti-SM antibodies but not by preimmune serum.
Surprisingly, luciferase mRNA was also immunoprecipitable in
association with SM, with an efficiency indistinguishable from that of
CAT mRNA. These data indicate that the presence or absence of a
specific SM-response element in the mRNA sequence is not a likely
explanation for the gene specificity displayed by SM. We initially
chose to pool luciferase plus SM- and CAT plus SM-transfected cells in
an effort to avoid potential complications introduced by competition
for SM in the same cell by the two target mRNA species and the
variables introduced by the unknown frequencies of cotransfection of
the three individual plasmids. However, we have subsequently repeated
the experiment by cotransfecting the three plasmids simultaneously and
we obtained a similar result (data not shown). These results therefore
indicate that although SM binds luciferase mRNA with considerable
affinity, similar to that which it displays for CAT mRNA, it
nevertheless does not significantly increase the cytoplasmic
accumulation of luciferase transcripts. This difference may reflect
intrinsic differences between the two mRNAs, such as the presence or
absence of binding motifs capable of mediating interaction with other
host cell proteins (see Discussion).

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 5.
SM binds to transcripts of SM-responsive and
SM-unresponsive genes. COS-7 cells were transfected with SM and CMV-CAT
or CMV-luc plasmids. Lysates were prepared 48 h after
transfection, pooled, and immunoprecipitated with either preimmune
serum (PI) or anti-SM antibodies (Ab). RNA was prepared from
immunoprecipitates, and RPA was performed to detect CAT and luciferase
mRNA. Total RNA was also prepared from pooled CMV-luc- and CMV-CAT-
transfected cells and analyzed in parallel (R). Control RPAs were also
performed with tRNA (t). Unhydrolyzed full-length luciferase and CAT
probes (which are approximately the same length) are also shown (f.l.).
mw, molecular size markers.
|
|
SM binds newly transcribed RNA.
The finding that SM was
capable of binding luciferase mRNA also raised the question of why SM
was apparently incapable of binding host GAPDH mRNA in the IP-RPAs
shown in Fig. 3. In fact, it was this apparently specific association
of SM with CAT mRNA, but not with GAPDH mRNA, that led to the
hypothesis that SM specifically associates with certain mRNAs. However,
GAPDH mRNA has a relatively low turnover rate, and the majority of the
steady-state amount of GAPDH mRNAs had been synthesized and processed
prior to the 48 h during which mRNA was synthesized from
transfected genes before RNA isolation. Thus, most of the GAPDH mRNA
present in the cells transfected with SM plasmid was not undergoing
nuclear posttranscriptional processing and was perhaps unavailable for interaction with SM. Consistent with such an analysis is the fact that
unlike the transfected reporter mRNAs, the majority of GAPDH mRNA
detected by Northern blotting was found in the cytoplasm (Fig. 4B). We
therefore performed the following experiment to ask whether SM could
bind newly transcribed GAPDH mRNA. We first cloned the human GAPDH cDNA
in the same CMV promoter-driven expression vector as had been used for
our other reporter genes. In order to be able to differentiate newly
synthesized GAPDH mRNA from host cell GAPDH mRNA, we inserted a small
DNA fragment from the
-lactamase gene upstream of the initiator
codon for GAPDH in the GAPDH expression vector, as described in
Materials and Methods. This addition allowed the differentiation of
transcripts derived from the transfected GAPDH gene from those derived
from the endogenous host cell GAPDH gene. We transfected COS-7 cells
with the marked GAPDH expression vector and either SM or control
plasmid. Forty-eight hours after transfection, lysates were prepared as
described previously and immunoprecipitated with either anti-SM
antibodies or preimmune serum. RNA was prepared from the
immunoprecipitates and analyzed for the presence of GAPDH transcripts
by RPA. As shown in Fig. 6, when RNA
isolated directly from the transfected cells was simultaneously measured by RPA, the transfected GAPDH gene was seen to be
expressed at levels comparable to those of the host cell GAPDH gene. As was the case in previous experiments, such as the one shown in Fig. 3,
host cell-derived GAPDH mRNA was not detectable in association with SM.
However, anti-SM antibodies did immunoprecipitate GAPDH mRNA newly
transcribed from the transfected GAPDH gene. It should also be noted
that SM associated only with the latter RNA species (derived from
transfected GAPDH gene) despite the fact that the endogenous cellular
GAPDH mRNA was present in similar amounts (Fig. 6). Approximately 10%
of the total RNA derived from the transfected GAPDH gene was recovered
in association with SM, an efficiency comparable to that seen with
luciferase and CAT mRNA. These data suggest that SM-RNA association in
vivo may be sequence independent but occurs primarily with newly
transcribed RNA, perhaps in association with one or more of the
multiple steps in posttranscriptional RNA processing.

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 6.
SM binds to newly synthesized RNA. COS-7 cells were
transfected with SM and either GAPDH cDNA plasmid (cGAPDH) or empty
vector. Cell lysates were immunoprecipitated with preimmune serum (PI)
or anti-SM antibodies (Ab). RNA was prepared from immunoprecipitates
and RPA was performed to detect GAPDH RNAs. Total RNA from each set of
transfected cells was prepared and analyzed by RPA in parallel (R). The
sizes of fragments protected by RNA from transfected GAPDH (cGADPH) or
endogenous cellular GAPDH (GAPDH) are shown at the right. Probe
incubated with tRNA was also analyzed in parallel as a specificity
control (t).
|
|
 |
DISCUSSION |
SM protein, like its homologs in other herpesviruses, is a
posttranscriptional regulator of gene expression. Although many of
these proteins have been extensively studied, many aspects of their
interaction with mRNA remain incompletely understood. In this report,
we have demonstrated that SM protein associates with newly transcribed
mRNA molecules in vivo and we have further characterized several
aspects of its interaction with RNA. SM had previously been shown to
bind RNA in vitro, and it had been suggested that such binding was
target-RNA specific. SM contains a highly arginine-rich region, and
arginine-containing motifs of ICP27 have been linked to its ability to
bind RNA (41, 42). Although the arginine-rich domain of
the SM protein was absolutely required for the ability of SM to bind
RNA in vitro, we found that this domain and the ability to bind RNA in
vitro were dispensable for its gene activation function. The ability of
the RXP triplet domain to mediate in vitro RNA binding was in fact
dependent on cleavage or truncation of the full-length SM protein such
that the RXP domain became the 3'-terminal portion of the protein. Further, mutant SM protein lacking the RXP domain was stable in vivo
and localized normally in the nucleus of transfected cells. Buisson et
al. have previously shown by reverse transcription-PCR that SM mutants
lacking this region are nevertheless capable of facilitating the
cytoplasmic accumulation of reporter mRNAs (4). These data
indicate that while the RXP domain may play some other role in native
SM function, its ability to bind RNA in vitro is not relevant to
SM-mediated gene activation or intracellular localization.
Although the RXP domain was dispensable for SM function, the question
as to whether SM physically associates with mRNA in vivo remained to be
answered. Based on several lines of evidence, it appeared likely that
SM interacts with RNA directly or in concert with other proteins. SM
does not directly increase the rate of transcript initiation of
activated target genes as measured in nuclear run-on assays
(45). However, the amounts of nuclear and cytoplasmic CAT
mRNA, in both the total and polyadenylated fractions, are increased in
cells expressing SM (45). SM, like the herpesvirus saimiri
ORF57 and HSV ICP27 gene products, colocalizes with splicing components
in cell nuclei (13, 48, 50). SM has been reported to
associate with proteins involved in pre-mRNA processing and nuclear
export, including hnRNP C, exportin 1 (CRM 1), and the nucleoporin Nup
214 (Can) (2, 32). SM also enhances pre-mRNA processing of
the EBV DNA polymerase transcript (32). Using the methods
described in this report, we have shown that specific mRNAs can be
detected in complexes with SM protein. There are several notable
aspects to these SM-RNA interactions. First, a significant proportion
of the target mRNA present in the cell is found in association with SM.
Based on the amount of total CAT and luciferase mRNA present in the
cell lysate, at least 10% was precipitated by anti-SM antibodies.
Second, the association appears to be confined to newly transcribed
mRNAs. This conclusion is based on the fact that mRNA transcribed from
a transfected GAPDH gene was associated with SM but cellular GAPDH mRNA
was not. It should be noted that the association of SM detected in these experiments may be indirect and mediated by one or more RNA-binding proteins, since the experimental conditions were designed to maintain protein-protein interactions.
It has been previously shown that SM activates some but not all genes,
whether of EBV, bacterial, or eukaryotic origin (39, 45,
50). We have demonstrated in this report that gene specificity of SM activation correlates with the ability of SM to increase the
cytoplasmic accumulation of the target mRNA. It was therefore an
attractive hypothesis that SM specificity might depend on the presence
of SM binding elements in SM-responsive mRNAs. Such response elements
are the basis for nuclear export of unspliced viral RNAs of HIV,
Mason-Pfizer monkey virus, and related type D retroviruses (3,
38). In both cases, the viral RNA is bound by a viral protein
(HIV rev) or host cell proteins that facilitate nuclear RNA export.
Similarly, a positive processing element in the HSV thymidine kinase
mRNA is specifically bound by hnRNP L and enhances expression of
thymidine kinase and also other intronless transcripts to which it is
linked (36). Somewhat surprisingly, we found that SM bound
luciferase mRNA and CAT mRNA with equal affinity, although luciferase
expression was completely unresponsive to SM. These data therefore
strongly suggest that SM specificity is not based solely on the ability
of SM to interact with the target mRNA.
Interestingly, a moderate but consistent increase in nuclear
accumulation of target mRNA was observed when SM was coexpressed, regardless of whether the target gene was SM responsive. Thus, nuclear
CAT, luciferase, and hGH RNA levels were all increased by SM, although
only cytoplasmic CAT mRNA amounts and CAT protein activity were
significantly increased by SM. These data suggest that SM may generally
enhance the nuclear accumulation of nascent RNA transcripts. However,
it appears that other factors determine whether SM is also capable of
enhancing the cytoplasmic accumulation of mRNA to which it is bound.
There are several possible mechanisms by which such selectivity might
operate. First, SM-nonresponsive genes, such as luciferase and EBV
BBLF2/3, may contain nuclear restriction elements that SM cannot
overcome. Such elements may consist of binding sites for cellular
proteins that limit the rate of nuclear export. Alternatively, the
mRNAs of responsive genes such as CAT and EBV BMRF1 may contain binding
sites for one or more cellular proteins that SM cooperates with to
facilitate cytoplasmic accumulation. Intronless genes, in particular,
may contain distinctive protein-binding mRNA sequence elements that compensate for the intrinsic inefficiency with which they are exported
to the cytoplasm (24, 26-28, 36). The presence of such
elements may therefore lead to the assembly of a unique set of proteins
on individual mRNPs. Such differences in the proteins which decorate
each mRNP would be expected to have various effects on its nuclear export.
It has been well established that the presence of introns in a gene
facilitates cytoplasmic accumulation of the final spliced mRNA
(25). Injection of synthesized intronless mRNA into
Xenopus oocyte nuclei leads to inefficient cytoplasmic
accumulation of the mRNA (37). It has recently been shown
that in the process of splicing, certain cell proteins remain attached
after detachment of spliceosome components (29, 34, 55).
These proteins, such as Aly and Y14, are predominantly nuclear
nucleocytoplasmic shuttling proteins and do not associate with mRNAs
from intronless cDNAs (29, 55). It is likely that SM plays
a role similar to these cell proteins in enhancing nuclear export of
viral intronless cDNAs, which would otherwise be at a disadvantage in
export to the cytoplasm. The net effect of SM on a specific mRNA is
therefore likely to be dependent on the other RNA-binding proteins
which comprise its mRNP particle. Further dissection of SM-responsive and nonresponsive mRNAs as well as identification of host cell proteins
which bind to SM should yield further insight into the mechanism of
posttranscriptional, gene-specific activation by SM.
 |
ACKNOWLEDGMENT |
This work was supported by Public Health Service grant CA 81133 from the National Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Florida Shands Cancer Center, Box 100232, University of Florida, 1600 SW Archer Rd., Gainesville, FL 32610-0232. Phone: (352) 392-9302. Fax:
(352) 392-5802. E-mail: sswamina{at}ufl.edu.
 |
REFERENCES |
| 1.
|
Bello, L. J.,
A. J. Davison,
M. A. Glenn,
A. Whitehouse,
N. Rethmeier,
T. F. Schulz, and J. B. Clements.
1999.
The human herpesvirus-8 ORF 57 gene and its properties.
J. Gen. Virol.
80:3207-3215[Abstract/Free Full Text].
|
| 2.
|
Boyle, S. M.,
V. Ruvolo,
A. K. Gupta, and S. Swaminathan.
1999.
Association with the cellular export receptor CRM 1 mediates function and intracellular localization of Epstein-Barr virus SM protein, a regulator of gene expression.
J. Virol.
73:6872-6881[Abstract/Free Full Text].
|
| 3.
|
Bray, M.,
S. Prasad,
J. W. Dubay,
E. Hunter,
K. T. Jeang,
D. Rekosh, and M. L. Hammarskjold.
1994.
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.
Proc. Natl. Acad. Sci. USA
91:1256-1260[Abstract/Free Full Text].
|
| 4.
|
Buisson, M.,
F. Hans,
I. Kusters,
N. Duran, and A. Sergeant.
1999.
The C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus protein EB2 is required for its effect on RNA splicing and transport.
J. Virol.
73:4090-4100[Abstract/Free Full Text].
|
| 5.
|
Buisson, M.,
E. Manet,
M. C. Trescol-Biemont,
H. Gruffat,
B. Durand, and A. Sergeant.
1989.
The Epstein-Barr Virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.
J. Virol.
63:5276-5284[Abstract/Free Full Text].
|
| 6.
|
Chavrier, P.,
H. Gruffat,
A. Chevalier-Greco,
M. Buisson, and A. Sergeant.
1989.
The Epstein-Barr Virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities.
J. Virol.
63:607-614[Abstract/Free Full Text].
|
| 7.
|
Chee, M., and B. Barrell.
1990.
Herpesviruses: a study of parts.
Trends Genet.
6:86-91[CrossRef][Medline].
|
| 8.
|
Cheung, P.,
K. S. Ellison,
R. Verity, and J. R. Smiley.
2000.
Herpes simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated alpha-globin pre-mRNA in infected HeLa cells.
J. Virol.
74:2913-2919[Abstract/Free Full Text].
|
| 9.
|
Chevalier-Greco, A.,
E. Manet,
P. Chavrier,
C. Mosnier,
J. Daillie, and A. Sergeant.
1986.
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.
EMBO J.
5:3243-3249[Medline].
|
| 10.
|
Cho, M. S.,
K. T. Jeang, and S. D. Hayward.
1985.
Localization of the coding region for an Epstein-Barr virus early antigen and inducible expression of this 60-kilodalton nuclear protein in transfected fibroblast cell lines.
J. Virol.
56:852-859[Abstract/Free Full Text].
|
| 11.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 12.
|
Cook, I. D.,
F. Shanahan, and P. J. Farrell.
1994.
Epstein-Barr virus SM protein.
Virology
205:217-227[CrossRef][Medline].
|
| 13.
|
Cooper, M.,
D. J. Goodwin,
K. T. Hall,
A. J. Stevenson,
D. M. Meredith,
A. F. Markham, and A. Whitehouse.
1999.
The gene product encoded by ORF 57 of herpesvirus saimiri regulates the redistribution of the splicing factor SC-35.
J. Gen. Virol.
80:1311-1316[Abstract].
|
| 14.
|
Davison, A. J., and P. Taylor.
1987.
Genetic relations between varicella-zoster virus and Epstein-Barr virus.
J. Gen. Virol.
68:1067-1079[Abstract/Free Full Text].
|
| 15.
|
DeNoto, F. M.,
D. D. Moore, and H. M. Goodman.
1981.
Human growth hormone DNA sequence and mRNA structure: possible alternative splicing.
Nucleic Acids Res.
9:3719-3730[Abstract/Free Full Text].
|
| 16.
|
Ellison, K. S.,
S. A. Rice,
R. Verity, and J. R. Smiley.
2000.
Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants.
J. Virol.
74:7307-7319[Abstract/Free Full Text].
|
| 17.
|
Farjot, G.,
M. Buisson,
M. Duc Dodon,
L. Gazzolo,
A. Sergeant, and I. Mikaelian.
2000.
Epstein-Barr virus EB2 protein exports unspliced RNA via a Crm-1-independent pathway.
J. Virol.
74:6068-6076[Abstract/Free Full Text].
|
| 18.
|
Farrell, P.
1989.
Epstein-Barr virus genome.
Adv. Viral Oncol.
8:103-132.
|
| 19.
|
Gluzman, Y.
1981.
SV40-transformed simian cells support the replication of early SV40 mutants.
Cell
23:175-182[CrossRef][Medline].
|
| 20.
|
Gupta, A. K.,
V. Ruvolo,
C. Patterson, and S. Swaminathan.
2000.
The human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is a posttranscriptional activator of gene expression.
J. Virol.
74:1038-1044[Abstract/Free Full Text].
|
| 21.
|
Hardwicke, M. A., and R. M. Sandri-Goldin.
1994.
The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection.
J. Virol.
68:4797-4810[Abstract/Free Full Text].
|
| 22.
|
Hardy, W. R., and R. M. Sandri-Goldin.
1994.
Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect.
J. Virol.
68:7790-7799[Abstract/Free Full Text].
|
| 23.
|
Hibbard, M. K., and R. M. Sandri-Goldin.
1995.
Arginine-rich regions succeeding the nuclear localization region of the herpes simplex virus type 1 regulatory protein ICP27 are required for efficient nuclear localization and late gene expression.
J. Virol.
69:4656-4667[Abstract].
|
| 24.
|
Huang, J., and T. J. Liang.
1993.
A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products.
Mol. Cell. Biol.
13:7476-7486[Abstract/Free Full Text].
|
| 25.
|
Huang, M. T. F., and C. M. Gorman.
1990.
Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA.
Nucleic Acids Res.
18:937-947[Abstract/Free Full Text].
|
| 26.
|
Huang, Y., and G. G. Carmichael.
1997.
The mouse histone H2a gene contains a small element that facilitates cytoplasmic accumulation of intronless gene transcripts and of unspliced HIV-1-related mRNAs.
Proc. Natl. Acad. Sci. USA
94:10104-10109[Abstract/Free Full Text].
|
| 27.
|
Huang, Y.,
K. M. Wimler, and G. G. Carmichael.
1999.
Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing.
EMBO J.
18:1642-1652[CrossRef][Medline].
|
| 28.
|
Huang, Z. M., and T. S. Yen.
1995.
Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts.
Mol. Cell. Biol.
15:3864-3869[Abstract].
|
| 29.
|
Kataoka, N.,
J. Yong,
V. N. Kim,
F. Velazquez,
R. A. Perkinson,
F. Wang, and G. Dreyfuss.
2000.
Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm.
Mol. Cell
6:673-682[CrossRef][Medline].
|
| 30.
|
Kenney, S.,
J. Kamine,
E. Holley-Guthrie,
E. C. Mar,
J. C. Lin,
D. Markovitz, and J. Pagano.
1989.
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent.
J. Virol.
63:3870-3877[Abstract/Free Full Text].
|
| 31.
|
Kenney, S.,
J. Kamine,
D. Markovitz,
R. Fenrick, and J. Pagano.
1988.
An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.
Proc. Natl. Acad. Sci. USA
85:1652-1656[Abstract/Free Full Text].
|
| 32.
|
Key, S. C.,
T. Yoshizaki, and J. S. Pagano.
1998.
The Epstein-Barr virus (EBV) SM protein enhances pre-mRNA processing of the EBV DNA polymerase transcript.
J. Virol.
72:8485-8492[Abstract/Free Full Text].
|
| 33.
|
Kirshner, J. R.,
D. M. Lukac,
J. Chang, and D. Ganem.
2000.
Kaposi's sarcoma-associated herpesvirus open reading frame 57 encodes a posttranscriptional regulator with multiple distinct activities.
J. Virol.
74:3586-3597[Abstract/Free Full Text].
|
| 34.
|
Le Hir, H.,
M. J. Moore, and L. E. Maquat.
2000.
Pre-mRNA splicing alters mRNP composition: evidence for stable association of proteins at exon-exon junctions.
Genes Dev.
14:1098-1108[Abstract/Free Full Text].
|
| 35.
|
Lieberman, P. M.,
P. O'Hare,
G. S. Hayward, and S. D. Hayward.
1986.
Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein.
J. Virol.
60:140-148[Abstract/Free Full Text].
|
| 36.
|
Liu, X., and J. E. Mertz.
1995.
HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression.
Genes Dev.
9:1766-1780[Abstract/Free Full Text].
|
| 37.
|
Luo, M. J., and R. Reed.
1999.
Splicing is required for rapid and efficient mRNA export in metazoans.
Proc. Natl. Acad. Sci. USA
96:14937-14942[Abstract/Free Full Text].
|
| 38.
|
Malim, M. H.,
J. Hauber,
S. Y. Le,
J. V. Maizel, and B. R. Cullen.
1989.
The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.
Nature
338:254-257[CrossRef][Medline].
|
| 39.
|
Markovitz, D. M.,
S. Kenney,
J. Kamine,
M. S. Smith,
M. Davis, and E.-S. Huang.
1989.
Disparate effects of two herpesviruses immediate-early gene trans-activators on the HIV LTR.
Virology
173:750-754[CrossRef][Medline].
|
| 40.
|
McGeoch, D. J.,
M. A. Dalrymple,
A. J. Davison,
A. Dolan,
M. C. Frame,
D. McNab,
L. J. Perry,
J. E. Scott, and P. Taylor.
1988.
The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.
J. Gen. Virol.
69:1531-1574[Abstract/Free Full Text].
|
| 41.
|
Mears, E., and S. A. Rice.
1996.
The RGG box motif of the herpes simplex virus ICP27 protein mediates an RNA-binding activity and determines in vivo methylation.
J. Virol.
70:7445-7453[Abstract].
|
| 42.
|
Mears, W. E.,
V. Lam, and S. A. Rice.
1995.
Identification of nuclear and nucleolar localization signals in the herpes simplex virus regulatory protein ICP27.
J. Virol.
69:935-947[Abstract].
|
| 43.
|
Menezes, J.,
W. Liebold,
G. Klein, and G. Clements.
1975.
Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional EBV-genome-negative African Burkitt's lymphoma.
Biomedicine
22:276-284[Medline].
|
| 44.
|
Perera, L. P.,
S. Kaushal,
P. R. Kinchington,
J. D. Mosca,
G. S. Hayward, and S. E. Straus.
1994.
Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homolog ICP27.
J. Virol.
68:2468-2477[Abstract/Free Full Text].
|
| 45.
|
Ruvolo, V.,
E. Wang,
S. Boyle, and S. Swaminathan.
1998.
The Epstein-Barr virus nuclear protein SM is both a post-transcriptional inhibitor and activator of gene expression.
Proc. Natl. Acad. Sci. USA
95:8852-8857[Abstract/Free Full Text].
|
| 46.
|
Sample, J.,
G. Lancz, and M. Nonoyama.
1986.
Mapping of genes in BamHI fragment M of Epstein-Barr virus DNA that may determine the fate of viral infection.
J. Virol.
57:145-154[Abstract/Free Full Text].
|
| 47.
|
Sandri-Goldin, R. M.
1998.
ICP27 mediates HSV RNA export by shuttling through a leucine-rich nuclear export signal and binding viral intronless RNAs through an RGG motif.
Genes Dev.
12:868-879[Abstract/Free Full Text].
|
| 48.
|
Sandri-Goldin, R. M.,
M. K. Hibbard, and M. A. Hardwicke.
1995.
The C-terminal repressor region of herpes simplex virus type 1 ICP27 is required for the redistribution of small nuclear ribonucleoprotein particles and splicing factor SC35; however, these alterations are not sufficient to inhibit host cell splicing.
J. Virol.
69:6063-6076[Abstract].
|
| 49.
|
Sandri-Goldin, R. M., and G. E. Mendoza.
1992.
A herpesvirus regulatory protein appears to act post-transcriptionally by affecting mRNA processing.
Genes Dev.
63:848-863.
|
| 50.
|
Semmes, O. J.,
L. Chen,
R. T. Sarisky,
Z. Gao,
L. Zhong, and S. D. Hayward.
1998.
Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein-Barr virus replication gene mRNA.
J. Virol.
72:9526-9534[Abstract/Free Full Text].
|
| 51.
|
Tso, J. Y.,
X. H. Sun,
T. H. Kao,
K. S. Reece, and R. Wu.
1985.
Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene.
Nucleic Acids Res.
13:2485-2502[Abstract/Free Full Text].
|
| 52.
|
Winkler, M.,
S. A. Rice, and T. Stamminger.
1994.
UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression.
J. Virol.
68:3943-3954[Abstract/Free Full Text].
|
| 53.
|
Wong, K.-M., and A. J. Levine.
1986.
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans.
J. Virol.
60:149-156[Abstract/Free Full Text].
|
| 54.
|
Xiao, L., and R. A. Casero, Jr.
1996.
Differential transcription of the human spermidine/spermine N3-acetyltransferase (SSAT) gene in human lung carcinoma cells.
Biochem. J.
313:691-696.
|
| 55.
|
Zhou, Z.,
M. J. Luo,
K. Straesser,
J. Katahira,
E. Hurt, and R. Reed.
2000.
The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans.
Nature
407:401-405[CrossRef][Medline].
|
Journal of Virology, July 2001, p. 6033-6041, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.6033-6041.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ricci, E. P., Mure, F., Gruffat, H., Decimo, D., Medina-Palazon, C., Ohlmann, T., Manet, E.
(2009). Translation of intronless RNAs is strongly stimulated by the Epstein-Barr virus mRNA export factor EB2. Nucleic Acids Res
0: gkp497v1-gkp497
[Abstract]
[Full Text]
-
Verma, D., Swaminathan, S.
(2008). Epstein-Barr Virus SM Protein Functions as an Alternative Splicing Factor. J. Virol.
82: 7180-7188
[Abstract]
[Full Text]
-
Bilello, J. P., Morgan, J. S., Desrosiers, R. C.
(2008). Extreme Dependence of gH and gL Expression on ORF57 and Association with Highly Unusual Codon Usage in Rhesus Monkey Rhadinovirus. J. Virol.
82: 7231-7237
[Abstract]
[Full Text]
-
Majerciak, V., Yamanegi, K., Allemand, E., Kruhlak, M., Krainer, A. R., Zheng, Z.-M.
(2008). Kaposi's Sarcoma-Associated Herpesvirus ORF57 Functions as a Viral Splicing Factor and Promotes Expression of Intron-Containing Viral Lytic Genes in Spliceosome-Mediated RNA Splicing. J. Virol.
82: 2792-2801
[Abstract]
[Full Text]
-
Han, Z., Marendy, E., Wang, Y.-D., Yuan, J., Sample, J. T., Swaminathan, S.
(2007). Multiple Roles of Epstein-Barr Virus SM Protein in Lytic Replication. J. Virol.
81: 4058-4069
[Abstract]
[Full Text]
-
Majerciak, V., Yamanegi, K., Nie, S. H., Zheng, Z.-M.
(2006). Structural and Functional Analyses of Kaposi Sarcoma-associated Herpesvirus ORF57 Nuclear Localization Signals in Living Cells. J. Biol. Chem.
281: 28365-28378
[Abstract]
[Full Text]
-
Han, Z., Swaminathan, S.
(2006). Kaposi's Sarcoma-Associated Herpesvirus Lytic Gene ORF57 Is Essential for Infectious Virion Production.. J. Virol.
80: 5251-5260
[Abstract]
[Full Text]
-
Toth, Z., Lischka, P., Stamminger, T.
(2006). RNA-binding of the human cytomegalovirus transactivator protein UL69, mediated by arginine-rich motifs, is not required for nuclear export of unspliced RNA. Nucleic Acids Res
34: 1237-1249
[Abstract]
[Full Text]
-
Hiriart, E., Gruffat, H., Buisson, M., Mikaelian, I., Keppler, S., Meresse, P., Mercher, T., Bernard, O. A., Sergeant, A., Manet, E.
(2005). Interaction of the Epstein-Barr Virus mRNA Export Factor EB2 with Human Spen Proteins SHARP, OTT1, and a Novel Member of the Family, OTT3, Links Spen Proteins with Splicing Regulation and mRNA Export. J. Biol. Chem.
280: 36935-36945
[Abstract]
[Full Text]
-
Nicewonger, J., Suck, G., Bloch, D., Swaminathan, S.
(2004). Epstein-Barr Virus (EBV) SM Protein Induces and Recruits Cellular Sp110b To Stabilize mRNAs and Enhance EBV Lytic Gene Expression. J. Virol.
78: 9412-9422
[Abstract]
[Full Text]
-
Sandri-Goldin, R. M.
(2004). Viral Regulation of mRNA Export. J. Virol.
78: 4389-4396
[Full Text]
-
Ruvolo, V., Sun, L., Howard, K., Sung, S., Delecluse, H.-J., Hammerschmidt, W., Swaminathan, S.
(2004). Functional Analysis of Epstein-Barr Virus SM Protein: Identification of Amino Acids Essential for Structure, Transactivation, Splicing Inhibition, and Virion Production. J. Virol.
78: 340-352
[Abstract]
[Full Text]
-
Hiriart, E., Bardouillet, L., Manet, E., Gruffat, H., Penin, F., Montserret, R., Farjot, G., Sergeant, A.
(2003). A Region of the Epstein-Barr Virus (EBV) mRNA Export Factor EB2 Containing an Arginine-rich Motif Mediates Direct Binding to RNA. J. Biol. Chem.
278: 37790-37798
[Abstract]
[Full Text]
-
Ruvolo, V., Navarro, L., Sample, C. E., David, M., Sung, S., Swaminathan, S.
(2003). The Epstein-Barr Virus SM Protein Induces STAT1 and Interferon-Stimulated Gene Expression. J. Virol.
77: 3690-3701
[Abstract]
[Full Text]
-
Hiriart, E., Farjot, G., Gruffat, H., Nguyen, M. V. C., Sergeant, A., Manet, E.
(2003). A Novel Nuclear Export Signal and a REF Interaction Domain Both Promote mRNA Export by the Epstein-Barr Virus EB2 Protein. J. Biol. Chem.
278: 335-342
[Abstract]
[Full Text]
-
Poppers, J., Mulvey, M., Perez, C., Khoo, D., Mohr, I.
(2002). Identification of a Lytic-Cycle Epstein-Barr Virus Gene Product That Can Regulate PKR Activation. J. Virol.
77: 228-236
[Abstract]
[Full Text]
-
Gruffat, H., Batisse, J., Pich, D., Neuhierl, B., Manet, E., Hammerschmidt, W., Sergeant, A.
(2002). Epstein-Barr Virus mRNA Export Factor EB2 Is Essential for Production of Infectious Virus. J. Virol.
76: 9635-9644
[Abstract]
[Full Text]
-
Boyer, J. L., Swaminathan, S., Silverstein, S. J.
(2002). The Epstein-Barr Virus SM Protein Is Functionally Similar to ICP27 from Herpes Simplex Virus in Viral Infections. J. Virol.
76: 9420-9433
[Abstract]
[Full Text]